NCT02847559 - Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Anaplastic (Malignant) MeningiomaAtypical MeningiomaGrade II MeningiomaGrade III MeningiomaRecurrent MeningiomaSupratentorial Meningioma

Interventions

BIOLOGICAL

Bevacizumab

Given IV

PROCEDURE

Electric Field Therapy

Undergo electric field therapy using Optune device

DEVICE

NovoTTF-200A Device

Undergo electric field therapy using Optune device

PROCEDURE

Quality-of-Life Assessment

Ancillary studies

Trial Locations (8)

19104

ACTIVE_NOT_RECRUITING

University of Pennsylvania, Philadelphia

27834

ACTIVE_NOT_RECRUITING

Vidant Medical Center, East Caroling University, Greenville

30309

COMPLETED

Piedmont Healthcare, Atlanta

33176

COMPLETED

Miami Cancer Institute, Miami

60045

ACTIVE_NOT_RECRUITING

Northwestern University- Lake Forest Hospital, Lake Forest

60190

RECRUITING

Northwestern Medicine/ Cadence Health - CDH, Winfield

60611

RECRUITING

Northwestern University, Chicago

90404

COMPLETED

John Wayne Cancer Center at Providence St. John's Health Center, Santa Monica

All Listed Sponsors

collaborator

NovoCure Ltd.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER